Treatment of anthracycline extravasations using dexrazoxane

Area of Science:

• Oncology
• Pharmacology

Background:

• Extravasation of cytotoxic agents, particularly anthracyclines, represents a critical medical emergency.
• Dexrazoxane is the sole FDA-approved antidote for anthracycline extravasation, demonstrating efficacy and moderate tolerability.

Purpose of the Study:

• To review the current management strategies for anthracycline extravasations.
• To compare the efficacy and application of dexrazoxane versus alternative therapies like topical dimethyl sulfoxide (DMSO) and cooling.

Main Methods:

• Literature review and synthesis of existing clinical data on anthracycline extravasation management.
• Analysis of treatment outcomes associated with dexrazoxane, topical DMSO, and cooling therapies.

Main Results:

• Dexrazoxane is effective, especially for large-volume anthracycline extravasations or those involving central venous access devices.
• Topical DMSO combined with cooling is a commonly described, non-invasive approach, particularly for smaller extravasations.
• Both dexrazoxane and non-invasive methods show varying degrees of success, with dexrazoxane generally well-tolerated.

Conclusions:

• While dexrazoxane is a valuable therapeutic option, its definitive indications require further clarification.
• The combination of topical DMSO and cooling remains a frequently utilized and effective strategy for managing smaller anthracycline extravasations.
• Optimal treatment selection may depend on the volume of extravasated agent and the route of administration.